scholarly journals Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID ‐19 pandemic: A single‐center real‐life experience

2020 ◽  
Vol 33 (4) ◽  
Author(s):  
Mariateresa Rossi ◽  
Chiara Rovati ◽  
Mariachiara Arisi ◽  
Simone Soglia ◽  
Piergiacomo Calzavara‐Pinton
Keyword(s):  
Atopic Dermatitis ◽  
Life Experience ◽  
Real Life ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Single Center

scholarly journals Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience

2020 ◽  
Vol 9 (3) ◽  
pp. 791 ◽  
Author(s):  
Silvia Ferrucci ◽  
Giovanni Casazza ◽  
Luisa Angileri ◽  
Simona Tavecchio ◽  
Francesca Germiniasi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Atopic Dermatitis ◽  
Rating Scale ◽  
Real Life ◽  
Life Quality ◽  
Depression Scale ◽  
Interleukin 4 ◽  
Severe Atopic Dermatitis ◽  
Single Center

Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical baseline data of 117 severe AD patients treated with dupilumab were collected. At baseline and at weeks 4 and 16, disease severity was assessed through the Eczema Area and Severity Index (EASI) and quality of life through the Dermatology Life Quality Index (DLQI) questionnaire, Patient-Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), Peak Pruritus Numerical Rating Scale (NRS-itch), and VAS-sleep. Response to dupilumab was defined as an improvement of ≥75% in EASI from baseline (EASI75). At multivariate analysis, AD onset before 18 years [OR, 2.9; 95% CI, 1.2–7.2; p = 0.0207] and absence of hypereosinophilia [OR, 2.24; 95% CI, 1.03–4.86; p = 0.0412] were identified as significant predictive parameters for response to dupilumab in terms of EASI75 at week 4 but not at week 16. Significant reductions in EASI, DLQI, POEM, HADS, NRS-itch, and VAS-sleep were found between week 4 versus baseline (p < 0.0001 for all) and week 16 versus baseline (p < 0.0001 for all). Early AD onset and absence of hypereosinophilia may be suggested as predictive markers of early response to dupilumab. We confirmed the efficacy and safety of this agent along with the improvement of life quality in severe AD patients.

scholarly journals Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma

2019 ◽  
Vol 29 (6) ◽  
pp. 648-654 ◽  
Author(s):  
Joanna Mangana ◽  
Florentia Dimitriou ◽  
Ralph Braun ◽  
Sabine Ludwig ◽  
Reinhard Dummer ◽  
...  
Keyword(s):  
Low Dose ◽  
Life Experience ◽  
Real Life ◽  
Stage Iii ◽  
Adjuvant Setting ◽  
Single Center ◽  
Stage Iii Melanoma

Atopic dermatitis in adolescents: effectiveness and safety of dupilumab in a 16‐week real‐life experience during the COVID ‐19 pandemic in Italy

2021 ◽  
Author(s):  
Luca Stingeni ◽  
Katharina Hansel ◽  
Elettra Antonelli ◽  
Giacomo Dal Bello ◽  
Cataldo Patruno ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Life Experience ◽  
Real Life

scholarly journals Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment

2019 ◽  
Vol 99 (9) ◽  
pp. 762-768 ◽  
Author(s):  
L Ariëns ◽  
K Nimwegen ◽  
M Shams ◽  
D Bruin ◽  
J Schaft ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Economic Burden ◽  
Systemic Treatment ◽  
Adult Patients ◽  
Severe Atopic Dermatitis
Sign in / Sign up

Export Citation Format

Share Document